Stock Events

Stock Events

Anthera Pharmaceuticals 

$0.000100
9
+$0.00+0% Wednesday 13:42

Statistics

Day High
0.0001
Day Low
0.0001
52W High
0.001
52W Low
0.00001
Volume
23,894
Avg. Volume
790
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Earnings

18NovExpected
Q4 2021
Q1 2022
Q2 2022
Q3 2022
Q1 2024
Q2 2024
Q3 2024
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2012
2013
2014
2015
2016
2017
0Revenue
-26.87MNet Income

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
AMGEN
AMGN
Mkt Cap224.63B
Amgen is a biotechnology company that develops and manufactures innovative human therapeutics, including treatments in areas that may overlap with Anthera's focus on autoimmune and inflammatory diseases.
Abbvie
ABBV
Mkt Cap440.83B
AbbVie operates in similar therapeutic areas as Anthera, including immunology and oncology, making it a direct competitor in the biopharmaceutical market.
Bristol-Myers Squibb
BMY
Mkt Cap130.39B
Bristol Myers Squibb is a global biopharmaceutical company with a strong portfolio in cardiovascular, oncology, and immune science, competing in the same space as Anthera.
Gilead Sciences
GILD
Mkt Cap171.56B
Gilead Sciences is a research-based biopharmaceutical company that discovers, develops, and commercializes innovative medicines in areas of unmet medical need, including treatments that could be in direct competition with Anthera's products.
Pfizer
PFE
Mkt Cap152.69B
Pfizer is a global pharmaceutical corporation with a broad range of products in various therapeutic areas, including those that compete with Anthera's focus areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap82.72B
Regeneron Pharmaceuticals specializes in the discovery, development, and commercialization of treatments for serious medical conditions, potentially competing with Anthera in the biotech space.
Vertex Pharmaceuticals
VRTX
Mkt Cap128.19B
Vertex Pharmaceuticals is known for creating transformative medicines for people with serious diseases, including cystic fibrosis, which may compete with Anthera's therapeutic areas.
Biogen
BIIB
Mkt Cap31B
Biogen is a biotechnology company that develops therapies for neurological and neurodegenerative diseases, potentially overlapping with Anthera's interest in autoimmune diseases.
Astrazeneca
AZN
Mkt Cap242.64B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including those in areas competing with Anthera.
Novartis
NVS
Mkt Cap286.78B
Novartis is a global healthcare company that provides solutions to address the evolving needs of patients worldwide, including in areas that may compete with Anthera's product pipeline.

About

Anthera Pharmaceuticals, Inc., a biopharmaceutical enterprise, concentrates on developing and commercializing therapeutic solutions for conditions with significant unmet medical needs. The company's pipeline includes Sollpura, an investigational non-porcine pancreatic enzyme replacement therapy in Phase III clinical trials for individuals with exocrine pancreatic insufficiency. It is also advancing Blisibimod, currently in Phase II clinical evaluation for B-cell mediated autoimmune diseases, such as immunoglobulin A nephropathy (IgA nephropathy). Anthera holds licensing agreements with Amgen, Inc. and Eli Lilly and Company. Founded in 2004, the company's base of operations is in Houston, Texas.
Show more...
CEO
Paul F. Truex
Employees
21
Country
United States
ISIN
US03674U3005

Listings

STU
DE
6TA2.STU
OTC Link
US
ANTH

0 Comments

Share your thoughts

FAQ

What is Anthera Pharmaceuticals stock price today?▼
The current price of ANTH is $0.00 USD — it has increased by +0% in the past 24 hours. Watch Anthera Pharmaceuticals stock price performance more closely on the chart.
What is Anthera Pharmaceuticals stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Anthera Pharmaceuticals stocks are traded under the ticker ANTH.
Is Anthera Pharmaceuticals stock price growing?▼
ANTH stock has risen by +0% compared to the previous week, the month change is a +0% rise, over the last year Anthera Pharmaceuticals has showed a +0% increase.
What is Anthera Pharmaceuticals revenue for the last year?▼
Anthera Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Anthera Pharmaceuticals net income for the last year?▼
ANTH net income for the last year is -26.87M USD.
How many employees does Anthera Pharmaceuticals have?▼
As of August 20, 2026, the company has 21 employees.
In which sector is Anthera Pharmaceuticals located?▼
Anthera Pharmaceuticals operates in the Health & Wellness sector.
When did Anthera Pharmaceuticals complete a stock split?▼
The last stock split for Anthera Pharmaceuticals was on May 01, 2017 with a ratio of 1:8.
Where is Anthera Pharmaceuticals headquartered?▼
Anthera Pharmaceuticals is headquartered in Houston, United States.